Af­ter con­sumer spin­off, John­son & John­son re­ports Q3 sales in­crease and bumps up full-year guid­ance

As it sharp­ens its fo­cus on new med­i­cines and medtech, John­son & John­son says the lat­est re­sults lay a “sol­id foun­da­tion” for growth.

J&J’s third quar­ter rev­enues re­leased to­day are the first since it spun off its con­sumer health busi­ness in­to Ken­vue, which car­ries house­hold brands that in­clude Neu­tro­ge­na, Tylenol and Band-Aid. The move brought in $13.2 bil­lion in cash pro­ceeds, ac­cord­ing to a pre­sen­ta­tion.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER